Evolus, Inc. (EOLS)

Market Cap	593.18M
Revenue (ttm)	275.46M
Net Income (ttm)	-56.20M
Shares Out	64.48M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,122,280
Open	9.11
Previous Close	9.21
Day's Range	9.00 - 9.62
52-Week Range	8.67 - 17.82
Beta	1.00
Analysts	Strong Buy
Price Target	23.75 (+157.59%)
Earnings Date	Jul 30, 2025

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 332
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $23.75, which is an increase of 157.59% from the latest price.

Price Target

$23.75

(157.59% upside)

Analyst Consensus: Strong Buy